论文部分内容阅读
[目的]研究脂质体阿霉素对人喉癌HEP-2细胞株的作用特点。[方法]以MTT法分别测定脂质体阿霉素组与游离阿霉素组分别作用于HEP-2细胞株72h后的细胞增殖抑制率并比较两组的半数抑制浓度(IC50);通过流式细胞仪(FCM)检测两组药物分别作用于HEP-2细胞株72h后对其细胞周期的影响;采用荧光分光光度法分别测定脂质体阿霉素和游离阿霉素分别作用于HEP-2细胞株1、3、6h后实验细胞内的药物浓度。[结果]脂质体阿霉素对HEP-2细胞株的IC50是游离阿霉素的1/4倍。脂质体阿霉素组与游离阿霉素组分别采用0.016μg/ml、0.06μg/ml的浓度作用于HEP-2细胞株72h后,均使HEP-2细胞株停滞于G2/M期,且脂质体阿霉素G2/M期百分率高于游离阿霉素。荧光分光光度法结果显示:脂质体阿霉素组内药物浓度在1、3、6h后均分别大于游离阿霉素组,且6h后脂质体阿霉素作用于HEP-2细胞株内的阿霉素浓度是游离阿霉素的4倍。[结论]与游离阿霉素相比,脂质体阿霉素对人喉癌HEP-2细胞株具有较好的增殖抑制作用,并且阻滞HEP-2细胞株于G2/M,其可能机制是与脂质体阿霉素增加细胞内阿霉素浓度有关。
[Objective] To study the effect of liposomal doxorubicin on human laryngeal carcinoma HEP-2 cell line. [Method] The cell proliferation inhibition rates of HEP-2 cells treated with liposomal doxorubicin and free doxorubicin for 72 hours were determined respectively by MTT method and the IC50 values were compared. The effects of two drugs on the cell cycle of HEP-2 cells were detected by FCM. The fluorescence intensity of doxorubicin and free doxorubicin were measured respectively by fluorescence spectrophotometry in HEP- 2 cell line 1,3,6 h after intracellular drug concentration. [Result] The IC50 of liposomal doxorubicin on HEP-2 cell line was 1/4 times of that of free doxorubicin. HEP-2 cells were arrested in G2 / M phase after treated with 0.016μg / ml and 0.06μg / ml of HEP-2 cells for 72h in liposomal doxorubicin group and free doxorubicin group respectively, And the percentage of G2 / M phase of liposomal doxorubicin was higher than that of free doxorubicin. Fluorescence spectrophotometry showed that the concentration of drug in the liposomal doxorubicin group was higher than that of the free doxorubicin group after 1, 3 and 6 hours, respectively, and the liposomal doxorubicin was treated in the HEP-2 cell line after 6 hours The doxorubicin concentration is 4 times that of free doxorubicin. [Conclusion] Compared with free doxorubicin, liposomal doxorubicin has a good proliferation inhibitory effect on human laryngeal carcinoma HEP-2 cell line and blocks the possible mechanism of HEP-2 cell line in G2 / M Is associated with liposomal doxorubicin increased intracellular doxorubicin concentration.